ENYO Pharma selected to take part in the French Tech 120 FT120 program
ENYO Pharma has been selected to take part in the French Tech 120 #FT120 program for the second consecutive year. We will thus benefit from specific guidance and visibility. Created by the French government, this program offers support to French scaleups with the potential to become global technology leaders.
https://lafrenchtech.com/en/how-france-helps-startups/ft120/
Read next in 'Latest news'
- Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
- New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH
- New publication : An anti-diabetic drug targets NEET (CISD) proteins through destabilization of their [2Fe-2S] clusters
- Swiss NASH Foundation sponsorship
- ENYO Pharma in the Top 50 of the EIC ScalingUp List